These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3488125)

  • 1. Modified cyclophosphamide, vincristine, methotrexate, leucovorin, and cytarabine (COMLA) in intermediate- and high-grade lymphoma: an effective short-course regimen.
    Baer MR; Stein RS; Greer JP; Wolff SN; Hainsworth JD; Flexner JM
    Cancer Treat Rep; 1986 Jun; 70(6):785-7. PubMed ID: 3488125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
    Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
    Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma.
    Prokocimer M; Modan M; Rusoshansky S; Bairey O; Shaklai M
    Anticancer Res; 1989; 9(4):1233-5. PubMed ID: 2479327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, oncovin, methotrexate, leucovorin, cytosine arabinoside): a 10-year experience in a single institution.
    Gaynor ER; Ultmann JE; Golomb HM; Sweet DL
    J Clin Oncol; 1985 Dec; 3(12):1596-604. PubMed ID: 3877790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype.
    Marotta G; Bigazzi C; Bocchia M; Forconi F; Lauria F
    Haematologica; 1998 Sep; 83(9):853-4. PubMed ID: 9825583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary chemotherapy for localized non-Hodgkin's lymphomas with diffuse histologic characteristics. Preliminary report of a prospective study.
    Gomez GA; Reddy S; Krishnamsetty RM; Barcos M; Nava H; Han T; Ozer H; Henderson ES
    Arch Intern Med; 1986 Sep; 146(9):1785-8. PubMed ID: 3489446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
    Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR
    Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies.
    Anderson KC; Skarin AT; Rosenthal DS; MacIntyre JM; Pinkus GS; Case DC; Leonard RC; Canellos GP
    Cancer Treat Rep; 1984 Nov; 68(11):1343-50. PubMed ID: 6209007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Malignant lymphomas. Preliminary report of the National Protocol of Antineoplastic Drugs].
    Gutiérrez J; Osorio G; García H; Vacarezza R; Cao C
    Rev Med Chil; 1991 Sep; 119(9):990-1000. PubMed ID: 1726958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
    Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Non-Hodgkin's lymphomas: recent achievements and therapeutic perspectives].
    Bron D; Vandenheule B; Stryckmans P
    Rev Med Brux; 1985 Sep; 6(7):491-5. PubMed ID: 2417298
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP.
    Olopade OI; Larson RA; Mick R; Watson SM; Hoffman PC; Ultmann JE; Golomb HM
    Leukemia; 1990 Feb; 4(2):127-31. PubMed ID: 1689439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
    Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
    Kujawski LA; Longo WL; Williams EC; Turman NJ; Brandt N; Mosher DF; Eickhoff JC; Kahl BS
    Cancer Invest; 2007 Mar; 25(2):87-93. PubMed ID: 17453819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome.
    Choi KA; Lee JE; Kim YG; Kim DJ; Kim K; Ko YH; Oh HY; Kim WS; Huh W
    Ann Hematol; 2009 Jul; 88(7):639-45. PubMed ID: 19030857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of treatment of 112 cases of primary CNS lymphoma.
    Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
    Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.